OnabotulinumtoxinA improves oral aperture in patients with scleroderma: A small clinical trial
This study suggests that onabotulinumtoxinA is an efficacious short-term treatment for microstomia in scleroderma, and physicians should consider it to improve symptoms.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Cristian D. Gonzalez, Jarod John Pamatmat, Kevin M. Burningham, Michelle Yang, Heather W. Goff Source Type: research